Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis
H Michael Arrighi, Jerome Barakos, Frederik Barkhof, Donatella Tampieri, Clifford Jack Jr, Denis Melançon, Kristen Morris, Nzeera Ketter, Enchi Liu, H Robert Brashear, H Michael Arrighi, Jerome Barakos, Frederik Barkhof, Donatella Tampieri, Clifford Jack Jr, Denis Melançon, Kristen Morris, Nzeera Ketter, Enchi Liu, H Robert Brashear
Abstract
Background: Amyloid-related imaging abnormalities due to haemosiderin deposition (ARIA-H) occur in patients with mild to moderate dementia due to Alzheimer's disease (AD) and have been reported with increased incidence in clinical trials of amyloid-lowering therapies under development for AD.
Objective: Our objective was to explore the relationship between the incidences of ARIA-H during treatment with placebo and different doses of bapineuzumab, a humanised monoclonal antibody directed against amyloid β.
Methods: Two neuroradiologists independently reviewed 2572 GRE/T2* MRI sequences from 262 participants in two phase two clinical trials of bapineuzumab and an open-label extension study. Readers were blinded to the participant's therapy, APOE ε4 genotype and medical history.
Results: Several risk factors for small ARIA-H <10 mm (microhaemorrhages) were identified: APOE ε4, bapineuzumab treatment, pre-existing small ARIA-H and use of antithrombotics. The HR (95%CI) for incident ARIA-H <10 mm associated with the number of APOE ε4 alleles was 11.9 (3.3 to 42.5) for 2 versus no alleles and 3.5 (1.0 to 12.0) for 1 versus no allele. The HR for bapineuzumab therapy was 3.5 (1.0 to 12.0); for the presence of baseline ARIA-H <10 mm, it was 3.5 (1.6 to 7.8), and for the use of antithrombotic agents it was 2.2 (1.0 to 4.8). The incidence rate for ARIA-H <10 mm was elevated only in the initial 6 months of active treatment and declined after this interval to a rate similar to that observed in the group treated with placebo.
Conclusions: ARIA-H represents a spectrum of MRI findings due to haemosiderin deposition that appears to be related to impaired vascular integrity. The increased risk for ARIA-H associated with APOE ε4 allele frequency, pre-existing ARIA-H, treatment with bapineuzumab and use of antithrombotic agents provides additional support for this hypothesis of loss of integrity of cerebral vessels due to amyloid burden.
Trial registration: NCT00112073 and NCT00606476.
Keywords: ALZHEIMER'S DISEASE; AMYLOID; MRI; NEUROEPIDEMIOLOGY.
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/
Figures
References
- Jeerakathil T, Wolf PA, Beiser A, et al. . Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham study. Stroke 2004;35:1831–5. 10.1161/01.STR.0000131809.35202.1b
- Vernooji MW, van der Lugt A, Ikram MA, et al. . Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurol 2008;70:1208–14. 10.1212/01.wnl.0000307750.41970.d9
- Cordonnier C, van der Flier WM, Sluimer JD, et al. . Prevalence and severity of microbleeds in a memory clinic setting. Neurol 2006;66:1356–60. 10.1212/
- Hanyu H, Tanaka Y, Shimizu S, et al. . Cerebral microbleeds in Alzheimer's disease. J Neurol 2003;250:1496–7. 10.1007/s00415-003-0245-7
- Nakata-Kudo Y, Mizuno T, Yamada K, et al. . Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 2006;22:8–14. 10.1159/000092958
- Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. . Microbleed topography, leukoaraiosis, and cognition in probably Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 2008;65:790–5. 10.1001/archneur.65.6.790
- Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design. Brain 2007;130:1988–2003. 10.1093/brain/awl387
- Goos JDC, Teunissen CE, Veerhuis R, et al. . Microbleeds related to altered amyloid-beta metabolism in Alzheimer's disease. Neurobiol Aging 2012;33:1011.e1–9. 10.1016/j.neurobiolaging.2011.10.026
- Sperling RA, Jack CR Jr, Black SE, et al. . Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer Dement 2011;7:367–85. 10.1016/j.jalz.2011.05.2351
- Zago W, Schroeter S, Guido T, et al. . Vascular alterations in PDAPP mice after anti-A immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimer Dement 2013;9:S105–15. 10.1016/j.jalz.2012.11.010
- Rinne JO, Brooks DJ, Rossor MN, et al. . 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363–72. 10.1016/S1474-4422(10)70043-0
- Salloway S, Sperling R, Gilman S, et al. . A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061–70. 10.1212/WNL.0b013e3181c67808
- Gregoire SM, Chaudhary UJ, Brown MM, et al. . The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 2009;73:1759–66. 10.1212/WNL.0b013e3181c34a7d
- Wahlund LO, Barkhof F, Fazekas F, et al. . A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318–22. 10.1161/01.STR.32.6.1318
- Tolappanen AM, Lavikainen P, Soloman A, et al. . Incidence of stroke in people with Alzheimer disease: a national register-based approach. Neurology 2013;80:353–8. 10.1212/WNL.0b013e31827f08c5
- Salloway S, Sperling R, Fox NC, et al. . Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer's disease. New Eng J Med 2014;370:322–33. 10.1056/NEJMoa1304839
- Greenberg SM, Rebeck GW, Vonsattel JPG, et al. . Apolipoprotein E epsilon 4 and cerebral hemorrahge associated with amyloid angioapathy. Ann Neurol 1995;38:254–9. 10.1002/ana.410380219
- Goos JDC, Henneman WJP, Sluimer JD, et al. . Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurol 2010;74:1954–60. 10.1212/WNL.0b013e3181e396ea
- Goos JDC, Kester MI, Barkhof F, et al. . Patients with Alzheimer disease with multiple microbleeds: relationship with cerebrospinal fluid biomarkers and cognition. Stroke 2009;49:3455–60. 10.1161/STROKEAHA.109.558197
- Loehrer E, Ikram MA, Akoudad S, et al. . Apolipoprotein E genotype influences spatial distribution of microbleeds. Neurobiol Aging 2014;35:899–905. 10.1016/j.neurobiolaging.2013.09.012
- Caselli RJ, Walker D, Sue L, et al. . Amyloid load in nondemented brains correlates with APOE ε4. Neurosci Lett 2010;473:168–71. 10.1016/j.neulet.2010.02.016
- Pfeifer M, Boncristiano S, Bondolfi L, et al. . Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002;298:1379 10.1126/science.1078259
- Boche D, Zotova E, Weller RO, et al. . Consequences of Aβ immunisation on the vasculature of human Alzheimer's disease brain. Brain 2008;131:3299–310. 10.1093/brain/awn261
- Greenberg SM, O'Donnell HC, Schaefer PW, et al. . MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology 1999;53:1135–8. 10.1212/WNL.53.5.1135
- Kirsch W, McAuley G, Holshouser B, et al. . Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J Alzheimers Dis 2009;17:599–609. 10.3233/JAD-2009-1073
Source: PubMed